Literature DB >> 19339965

Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies.

C Fosser1, G Duczynski, M Agin, P Wicker, B Darpo.   

Abstract

We analyzed five crossover, thorough QT (TQT) studies to compare automated, manual, and computer-assisted (CA) measurement methods. All the methods detected moxifloxacin-induced, baseline-adjusted, placebo-subtracted mean changes in Fridericia-corrected QT interval (QTcF), with peak effect ranging from 10 to 21 ms. The variability associated with manual and CA measurements was generally 5-28% greater than that associated with automated methods. The performances of automated, manual, and CA measurements were comparable for the purpose of demonstrating assay sensitivity in TQT studies with healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339965     DOI: 10.1038/clpt.2009.34

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation.

Authors:  Julian Puppe; Deborah van Ooyen; Jeanne Neise; Fabinshy Thangarajah; Christian Eichler; Stefan Krämer; Roman Pfister; Peter Mallmann; Marina Wirtz; Guido Michels
Journal:  Breast Care (Basel)       Date:  2017-01-18       Impact factor: 2.860

Review 2.  The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.

Authors:  Borje Darpo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

3.  Man versus Machine: Comparison of Automated and Manual Methodologies for Measuring the QTc Interval: A Prospective Study.

Authors:  Jean T Barbey; Margaret Connolly; Brenda Beaty; Mori J Krantz
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-05-04       Impact factor: 1.468

4.  Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Authors:  Shuying Yang; Misba Beerahee
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

Review 5.  Drug-induced QT interval prolongation: mechanisms and clinical management.

Authors:  Senthil Nachimuthu; Manish D Assar; Jeffrey M Schussler
Journal:  Ther Adv Drug Saf       Date:  2012-10

6.  Plasma potassium concentration and cardiac repolarisation markers, Tpeak-Tend and Tpeak-Tend/QT, during and after exercise in healthy participants and in end-stage renal disease.

Authors:  Cao Thach Tran; Tania Atanasovska; Claus Graff; Jacob Melgaard; Jørgen K Kanters; Robert Smith; Aaron C Petersen; Keld P Kjeldsen; Michael J McKenna
Journal:  Eur J Appl Physiol       Date:  2022-01-20       Impact factor: 3.078

7.  Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population.

Authors:  Jonas B Nielsen; Claus Graff; Peter V Rasmussen; Adrian Pietersen; Bent Lind; Morten S Olesen; Johannes J Struijk; Stig Haunsø; Jesper H Svendsen; Lars Køber; Thomas A Gerds; Anders G Holst
Journal:  Eur Heart J       Date:  2014-03-06       Impact factor: 29.983

8.  Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation.

Authors:  Christian Funck-Brentano; Antonella Bacchieri; Giovanni Valentini; Silvia Pace; Silva Tommasini; Pascal Voiriot; David Ubben; Stephan Duparc; Eric Evene; Mathieu Felices; Marco Corsi
Journal:  Sci Rep       Date:  2019-01-28       Impact factor: 4.379

9.  QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.

Authors:  Sok-Sithikun Bun; Philippe Taghji; Johan Courjon; Fabien Squara; Didier Scarlatti; Guillaume Theodore; Delphine Baudouy; Benjamin Sartre; Mohamed Labbaoui; Jean Dellamonica; Denis Doyen; Charles-Hugo Marquette; Jacques Levraut; Vincent Esnault; Sok-Siya Bun; Emile Ferrari
Journal:  Clin Pharmacol Ther       Date:  2020-07-20       Impact factor: 6.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.